Anil K Giri
Overview
Explore the profile of Anil K Giri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1238
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Giri A, Subedi D, Kassel K
Appl Econ Perspect Policy
. 2023 Jan;
PMID: 36711012
This paper examines the payments made to minority producers, focused on African American producers, from the COVID-19 program, Coronavirus Food Assistance Program (CFAP), of the United States Department of Agriculture...
12.
Ianevski A, Giri A, Aittokallio T
Nucleic Acids Res
. 2022 May;
50(W1):W739-W743.
PMID: 35580060
SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, SynergyFinder has become a popular tool for multi-dose...
13.
Ianevski A, Giri A, Aittokallio T
Nat Commun
. 2022 Mar;
13(1):1246.
PMID: 35273156
Identification of cell populations often relies on manual annotation of cell clusters using established marker genes. However, the selection of marker genes is a time-consuming process that may lead to...
14.
Giri A, Ianevski A
Expert Opin Drug Discov
. 2021 Nov;
17(2):181-190.
PMID: 34743621
Introduction: The interactions between leukemic blasts and cells within the bone marrow environment affect oncogenesis, cancer stem cell survival, as well as drug resistance in hematological cancers. The importance of...
15.
Giri A
Front Pharmacol
. 2021 Mar;
11:620811.
PMID: 33658938
Discovery of markers predictive for 5-Fluorouracil (5-FU)-based adjuvant chemotherapy (adjCTX) response in patients with locally advanced stage II and III colon cancer (CC) is necessary for precise identification of potential...
16.
Ianevski A, Lahtela J, Javarappa K, Sergeev P, Ghimire B, Gautam P, et al.
Sci Adv
. 2021 Feb;
7(8).
PMID: 33608276
The extensive drug resistance requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to selectively target disease-driving cell subpopulations. To solve the combinatorial explosion challenge, we...
17.
Ianevski A, Giri A, Gautam P, Kononov A, Potdar S, Saarela J, et al.
Nat Mach Intell
. 2020 May;
1(12):568-577.
PMID: 32368721
High-throughput drug combination screening provides a systematic strategy to discover unexpected combinatorial synergies in pre-clinical cell models. However, phenotypic combinatorial screening with multi-dose matrix assays is experimentally expensive, especially when...
18.
Giri A, Prasad G, Bandesh K, Parekatt V, Mahajan A, Banerjee P, et al.
Mol Genet Genomics
. 2020 May;
295(4):1013-1026.
PMID: 32363570
Obesity, a risk factor for multiple diseases (e.g. diabetes, hypertension, cancers) originates through complex interactions between genes and prevailing environment (food habit and lifestyle) that varies across populations. Indians exhibit...
19.
Ianevski A, Giri A, Aittokallio T
Nucleic Acids Res
. 2020 Apr;
48(W1):W488-W493.
PMID: 32246720
SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both...
20.
Ianevski A, Timonen S, Kononov A, Aittokallio T, Giri A
PLoS Comput Biol
. 2020 Feb;
16(2):e1007604.
PMID: 32012154
Drug combinations are becoming a standard treatment of many complex diseases due to their capability to overcome resistance to monotherapy. In the current preclinical drug combination screening, the top combinations...